![Sean Bohen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sean Bohen
Amministratore Delegato presso
OLEMA PHARMACEUTICALS, INC.
Patrimonio netto: 2 M $ in data 30/09/2026
Profilo
Dr. Sean P.
Bohen is a President, Chief Executive Officer & Director at Olema Pharmaceuticals, Inc. He is on the Board of Directors at Gyroscope Therapeutics Ltd., Olema Pharmaceuticals, Inc. and AltruBio, Inc. Dr. Bohen was previously employed as a Non-Executive Director by Gyroscope Therapeutics Holdings Plc, a Chief Medical Officer & Executive Vice President by AstraZeneca PLC, a Senior Vice President-Early Development by Genentech, Inc., and an Associate by Howard Hughes Medical Institute, Inc. He received his undergraduate degree from the University of Wisconsin and a doctorate degree from The University of California, San Francisco.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 23/04/2026 | 237.650 ( 0,27% ) | 2 M $ | 30/09/2026 |
Posizioni attive di Sean Bohen
| Società | Posizione | Inizio |
|---|---|---|
| OLEMA PHARMACEUTICALS, INC. | Amministratore Delegato | 01/09/2020 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Develops gene therapies and medicines for eye diseases | Direttore/Membro del Consiglio | 11/09/2020 |
Altrubio, Inc.
 Altrubio, Inc. Pharmaceuticals: MajorHealth Technology Develops immunomodulators to target diseases of the immune system | Direttore/Membro del Consiglio | 01/08/2019 |
Precedenti posizioni note di Sean Bohen
| Società | Posizione | Fine |
|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Direttore/Membro del Consiglio | 17/02/2022 |
| ASTRAZENECA PLC | Direttore Tecnico/Scientifico/R&S | 14/01/2019 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01/07/2015 |
Howard Hughes Medical Institute, Inc.
 Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Corporate Officer/Principal | 01/01/2003 |
Formazione di Sean Bohen
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
94
Relazioni di 1° grado
9
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 9 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Howard Hughes Medical Institute, Inc.
Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Olema Pharmaceuticals, Inc.
 Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer | Health Technology |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Develops gene therapies and medicines for eye diseases | Health Technology |
Altrubio, Inc.
Altrubio, Inc. Pharmaceuticals: MajorHealth Technology Develops immunomodulators to target diseases of the immune system | Health Technology |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Develops clinical-stage gene therapies to treat diseases of eyes | Health Technology |
